(Bloomberg) -- Drugmaker Grifols SA and US short seller Gotham City Research are counting on two different reports from a Spanish regulator to bolster their cases as they prepare to face off in ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

That is below Grifols' current share price of around €11, and well shy of its near-€15 share price at the start of the year, ahead of a campaign by hedge fund Gotham City Research, which ...

(Guy Leblanc/Radio-Canada ) All three New Brunswick clinics are owned by Grifols, a Spanish multinational pharmaceutical and chemical manufacturer, formerly known as Canadian Plasma Resources.

After hours: January 28 at 4:57:48 PM EST Loading Chart for GRFS ...

Regulator says Gotham City attacks could be manipulation CNMV also says short seller right on some accounting issues Drugmaker Grifols SA and US short seller Gotham City Research are counting on two ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AlleyWatch sat down with Nucleus CEO and Founder Kian Sadeghi to learn more about the business, its future plans, and recent ...

Grifols has received a $21 million grant from The Michael J. Fox Foundation to fund a pioneering study aimed at identifying early biomarkers for Parkinson’s disease (PD). Grifols has received funding ...

At Texas A&M University, one research lab is changing the game of droplet microfluidics, a technique that involves conducting ...